子宫内膜癌前哨淋巴结评估:系统综述与Meta分析
该系统综述与Meta分析纳入55项研究、4915例子宫内膜癌女性,评估前哨淋巴结定位的诊断准确性与临床影响。总体检出率为81%(95%CI 77-84),双侧盆腔检出率50%(95%CI 44-56),腹主动脉旁检出率17%(95%CI 11-23);检测转移的敏感度为96%(95%CI 91-98)。与完整淋巴结清扫相比,前哨淋巴结定位组更可能接受辅助治疗。
要点
- 前哨淋巴结定位总体检出率81%,双侧盆腔检出率50%,腹主动脉旁检出率17%。
- 检测转移的敏感度为96%(95%CI 91-98),超分期未提高敏感度。
- 与完整淋巴结清扫相比,前哨淋巴结定位组更可能接受辅助治疗。
核心结论
- 前哨淋巴结定位在子宫内膜癌女性中是可行的,并能准确预测淋巴结状态。
- 当前数据支持使用宫颈注射技术联合吲哚菁绿。
- 前哨淋巴结定位可考虑作为子宫内膜癌分期的一种替代标准治疗。
研究设计与样本
- 系统综述与Meta分析,检索Medline、Embase和Cochrane对照试验中心注册库中2016年3月25日前发表的英文研究(PROSPERO CRD42016036503)。
- 纳入标准为包含10例及以上子宫内膜癌女性并报告前哨淋巴结定位检出率、敏感度和/或对治疗或生存影响的研究。
- 共纳入55项研究,包括4915例女性。
- 两名作者独立审阅摘要和全文并评估研究质量。
- 采用随机效应Meta分析和Meta回归合成检出率、敏感度及与成功定位相关的因素(研究规模、体重指数、肿瘤组织学和分级、注射部位、染料类型)。
主要发现
- 前哨淋巴结定位总体检出率为81%(95%CI 77-84),双侧盆腔淋巴结检出率为50%(95%CI 44-56),腹主动脉旁检出率为17%(95%CI 11-23)。
- 检出率在患者体重指数或肿瘤组织学和分级方面无差异。
- 与蓝色染料相比,使用吲哚菁绿增加了双侧检出率。
- 与其他注射技术相比,宫颈注射增加了双侧前哨淋巴结检出率但降低了腹主动脉旁检出率。
- 术中前哨淋巴结冰冻切片增加了总体和双侧检出率;检测转移的敏感度为96%(95%CI 91-98),超分期未提高敏感度。
临床怎么用
- 当前数据支持使用宫颈注射技术联合吲哚菁绿。
- 前哨淋巴结定位可考虑作为子宫内膜癌分期的一种替代标准治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the staging of endometrial cancer, controversy remains regarding the role of sentinel lymph node mapping compared with other nodal assessment strategies. OBJECTIVE: We conducted a systematic review to evaluate the diagnostic accuracy and clinical impact of sentinel lymph node mapping in the management of endometrial cancer. DATA SOURCES: We searched Medline, Embase, and the Cochrane Central Registry of Controlled trials for studies published in English before March 25, 2016 (PROSPERO CRD42016036503). STUDY ELIGIBILITY CRITERIA: Studies were included if they contained 10 or more women with endometrial cancer and reported on the detection rate, sensitivity, and/or impact on treatment or survival of sentinel lymph node mapping. STUDY APPRAISAL AND SYNTHESIS METHODS: Two authors independently reviewed abstracts and full-text articles for inclusion and assessed study quality. The detection rate, sensitivity, and factors associated with successful mapping (study size, body mass index, tumor histology and grade, injection site, dye type) were synthesized through random-effects meta-analyses and meta-regression. RESULTS: We identified 55 eligible studies, which included 4915 women. The overall detection rate of sentinel lymph node mapping was 81% (95% confidence interval, 77-84) with a 50% (95% confidence interval, 44-56) bilateral pelvic node detection rate and 17% (95% confidence interval, 11-23) paraaortic detection rate. There was no difference in detection rates by patient body mass index or tumor histology and grade. Use of indocyanine green increased the bilateral detection rate compared with blue dye. Additionally, cervical injection increased the bilateral sentinel lymph node detection rate but decreased the paraaortic detection rate compared with alternative injection techniques. Intraoperative sentinel lymph node frozen section increased the overall and bilateral detection rates. The sensitivity of sentinel node mapping to detect metastases was 96% (95% confidence interval, 91-98); ultrastaging did not improve sensitivity. Compared with women staged with complete lymphadenectomy, women staged with sentinel lymph node mapping were more likely to receive adjuvant treatment. CONCLUSION: Sentinel lymph node mapping is feasible and accurately predicts nodal status in women with endometrial cancer. The current data favors the use of cervical injection techniques with indocyanine green. Sentinel lymph mapping may be considered an alternative standard of care in the staging of women with endometrial cancer.
引用
- Bodurtha Smith AJ, Fader AN, Tanner EJ, et al. Sentinel lymph node assessment in endometrial cancer: a systematic review and meta-analysis. Am J Obstet Gynecol. 2016. PMID: 27871836. doi:10.1016/j.ajog.2016.11.1033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。